Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Lowered by StockNews.com

Vanda Pharmaceuticals (NASDAQ:VNDA) was downgraded by equities research analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Monday.

Separately, TheStreet cut Vanda Pharmaceuticals from a “c-” rating to a “d” rating in a report on Thursday, February 8th.

Vanda Pharmaceuticals Stock Performance

Shares of VNDA opened at $4.63 on Monday. The business’s 50-day moving average is $4.26 and its two-hundred day moving average is $4.07. The company has a market capitalization of $266.40 million, a P/E ratio of 92.60 and a beta of 0.76. Vanda Pharmaceuticals has a fifty-two week low of $3.30 and a fifty-two week high of $7.00.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, February 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.05. The company had revenue of $45.27 million for the quarter, compared to the consensus estimate of $37.00 million. Vanda Pharmaceuticals had a return on equity of 0.46% and a net margin of 1.30%. Analysts forecast that Vanda Pharmaceuticals will post -0.06 EPS for the current year.

Institutional Trading of Vanda Pharmaceuticals

Several institutional investors have recently made changes to their positions in VNDA. Los Angeles Capital Management LLC grew its stake in shares of Vanda Pharmaceuticals by 17.6% in the first quarter. Los Angeles Capital Management LLC now owns 431,224 shares of the biopharmaceutical company’s stock worth $1,772,000 after acquiring an additional 64,670 shares in the last quarter. GSA Capital Partners LLP grew its stake in shares of Vanda Pharmaceuticals by 39.8% during the fourth quarter. GSA Capital Partners LLP now owns 567,756 shares of the biopharmaceutical company’s stock worth $2,396,000 after purchasing an additional 161,737 shares in the last quarter. Aristides Capital LLC acquired a new position in shares of Vanda Pharmaceuticals during the fourth quarter worth $272,000. Tower Research Capital LLC TRC grew its stake in shares of Vanda Pharmaceuticals by 196.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 18,977 shares of the biopharmaceutical company’s stock worth $80,000 after purchasing an additional 12,568 shares in the last quarter. Finally, Pinnacle Wealth Planning Services Inc. acquired a new position in shares of Vanda Pharmaceuticals during the fourth quarter worth $87,000. Hedge funds and other institutional investors own 88.14% of the company’s stock.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.